Shah Keeren Rameshchandra 4

What Happened
Shah Keeren Rameshchandra, Chief Financial Officer of OKYO Pharma Ltd (OKYO), was granted a derivative award of 40,000 stock options on June 8, 2026. The reported exercise price is $1.85 per share, implying an aggregate exercise commitment of $74,000. This was an award/grant (derivative instrument), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-08; Filing date (Form 4): 2026-06-10 (timely filing).
• Transaction type/code: Award/Grant (derivative) — reported as acquisition (A).
• Quantity and terms: 40,000 options; exercise price $1.85; total exercise amount = $74,000.
• Vesting: 25% per year over four years, beginning on the first anniversary of the grant date.
• Shares owned after transaction: Not reported on this Form 4.
• No immediate sale or cashless exercise reported; this is a compensation grant, not a market purchase.

Context
Option grants are common executive compensation and do not create immediately tradable shares until vested and exercised. The four-year annual vesting schedule is a typical retention structure. For retail investors, awards indicate potential future insider exposure if options are exercised, but they are not the same signal as an insider buying shares with cash.